Abstract:Inflammatory bowel disease(IBD) is a chronic intestinal inflammatory disease, and additional nutritional support contributes to alleviate IBD symptoms. Studies have shown that dietary n-3 polyunsaturated fatty acids possess anti-inflammatory activity, while clinical trials have reported that additional supplementation with n-3 polyunsaturated fatty acids does not alleviate the disease symptoms in some IBD patients. Large-scale sequencing has revealed mutations in the n-3 polyunsaturated fatty acids receptor gene free fatty acid receptor 4(FFAR4). It remains unclear whether the variable effects of n-3 polyunsaturated fatty acids in IBD treatment are associated with the absence of the FFAR4 gene. In this study, the wild type(WT) and FFAR4 knockout (FFAR4KO) mice were used to establish the colitis models, concurrently supplemented with n-3 polyunsaturated fatty acids. The results showed that compared to those WT mice, the FFAR4KO mice exhibited more severer colitis under simultaneous n-3 polyunsaturated fatty acids supplementation, characterized by greater weight loss, higher disease activity index(DAI), increased colonic myeloperoxidase (MPO) activity, and higher mRNA levels of colonic inflammatory factors. This study provides a theoretical basis for precise nutritional intervention in IBD patients.
